Skip to Content
Merck
All Photos(1)

Key Documents

M2699

Sigma-Aldrich

Marimastat

≥98% (HPLC), solid, MMP inhibitor

Synonym(s):

BB2516, (2S,3R)-N4-[(1S)-2,2-Dimethyl-1-[(methylamino)carbonyl] propyl]-N1,2-dihydroxy-3-(2-methylpropyl)butanediamide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C15H29N3O5
CAS Number:
Molecular Weight:
331.41
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

Marimastat, ≥98% (HPLC)

Quality Level

Assay

≥98% (HPLC)

form

solid

solubility

DMSO: ≥20 mg/mL

shipped in

wet ice

storage temp.

−20°C

SMILES string

CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C

InChI

1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1

InChI key

OCSMOTCMPXTDND-OUAUKWLOSA-N

Gene Information

Application

Marimastat has been used as an inhibitor of:
  • metalloproteinase 2/9 (MMP2/9), to study its effects on exercise-mediated interleukin-6 (IL-6) release in mice
  • metalloproteinase, to determine protease activity in Pseudomonas aeruginosa cultures
  • metalloproteinase 10 (MMP10), to study its effect on monoclonal antibody H3 binding to MMP10

Biochem/physiol Actions

Marimastat is a broad spectrum matrix metalloprotease (MMP) inhibitor

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Amir S Razai et al.
The Journal of biological chemistry, 295(8), 2464-2472 (2020-01-19)
Since their discovery, the matrix metalloproteinase (MMP) family proteases have been considered as therapeutic targets in numerous diseases and disorders. Unfortunately, clinical trials with MMP inhibitors have failed to yield any clinical benefits of these inhibitors. These failures were largely
Stefanie K Menzies et al.
Toxicon: X, 14, 100118-100118 (2022-03-25)
Snakebite envenoming affects more than 250,000 people annually in sub-Saharan Africa. Envenoming by Dispholidus typus (boomslang) results in venom-induced consumption coagulopathy (VICC), whereby highly abundant prothrombin-activating snake venom metalloproteinases (SVMPs) consume clotting factors and deplete fibrinogen. The only available treatment
Nicholas J Youngman et al.
Molecules (Basel, Switzerland), 27(5) (2022-03-11)
Snakebite remains a significant public health burden globally, disproportionately affecting low-income and impoverished regions of the world. Recently, researchers have begun to focus on the use of small-molecule inhibitors as potential candidates for the neutralisation of key snake venom toxins
Timothy W Failes et al.
Journal of inorganic biochemistry, 101(3), 396-403 (2007-01-02)
Fe(III)-salen (N,N-bis(salicylidene)-ethane-1,2-diimine) complexes of simple hydroxamic acids and the MMP (matrix metalloproteinase) inhibitor marimastat have been evaluated as hypoxia activated drug carriers. The aceto- (aha), propion- (pha), benzohydroxamato (bha), and marimastat complexes were prepared and characterised by single crystal X-ray
Timothy W Failes et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 13(10), 2974-2982 (2006-12-16)
We report a potential means of selectively delivering matrix metalloproteinase (MMP) inhibitors to target tumour sites by use of a bioreductively activated Co(III) carrier system. The carrier, comprising a Co(III) complex of the tripodal ligand tris(methylpyridyl)amine (tpa), was investigated with

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service